Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2009

01-05-2009 | Epidemiology

Overweight, obesity and breast cancer prognosis: optimal body size indicator cut-points

Authors: Bilal Majed, Thierry Moreau, Bernard Asselain, Curie Institute Breast Cancer Group

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Login to get access

Abstract

Background Evidence from the data provided in numerous published articles indicates that obesity and overweight can have a negative prognosis role in breast cancer. However, different Body Size Indicators (BSI) and cut-points have been employed and may partly explain discrepancies between the findings of various studies. Material and methods 14,709 women were recruited, treated and followed for a first unilateral breast cancer. After randomly splitting the patients’ data into two groups, a maximum statistical outcome approach was used to select optimal BSI cut-points from a “training sample”, when prognosis events were investigated. External validation was then carried out using a “validation sample”, and agreement between the selected optimal BSI cut-points was assessed. Body Mass Index (BMI), weight (W), Ideal Weight Ratio (IWR) and Body Surface Area (BSA) were used, and were assessed at the time of diagnosis. Results The selected optimal BSI cut-points were reliable when overall survival, metastasis recurrence and disease free interval events were investigated. The chosen BMI cut-point values matched the overweight cut-point value given by the World Health Organization. Agreement between defined binary BSI was acceptable; however, it varied from “fair” to “very good”. Analysis of second primary cancer occurrence and contralateral recurrence events was not conclusive. When local and node recurrence events were taken into account, the results were inconsistent and were linked to an unconfirmed relationship between stoutness and these prognosis events. Conclusions Efficient, optimal BSI cut-points indicate a poorer prognosis, illustrated by a shortened overall survival and an increase of metastasis recurrences, from a BMI value of 25 kg/m², a W value of 60 kg, an IWR value of 20% and a BSA value of 1.7 m². Further BSI cut-point investigations are needed, taking into account contralateral recurrence and second primary cancer events.
Literature
3.
go back to reference Ryu SY, Kim CB, Nam CM, Park JK, Kim KS, Park J et al (2001) Is body mass index the prognostic factor in breast cancer? a meta-analysis. J Korean Med Sci 16(5):610–614PubMed Ryu SY, Kim CB, Nam CM, Park JK, Kim KS, Park J et al (2001) Is body mass index the prognostic factor in breast cancer? a meta-analysis. J Korean Med Sci 16(5):610–614PubMed
5.
go back to reference Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B (2007) Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B (2007) Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat
6.
go back to reference (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894:i–xii, 1–253. (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894:i–xii, 1–253.
8.
go back to reference Garrow JS, Webster J (1985) Quetelet’s index (W/H2) as a measure of fatness. Int J Obes 9(2):147–153PubMed Garrow JS, Webster J (1985) Quetelet’s index (W/H2) as a measure of fatness. Int J Obes 9(2):147–153PubMed
10.
go back to reference Swinburn BA, Craig PL, Daniel R, Dent DP, Strauss BJ (1996) Body composition differences between Polynesians and Caucasians assessed by bioelectrical impedance. Int J Obes Relat Metab Disord 20(10):889–894PubMed Swinburn BA, Craig PL, Daniel R, Dent DP, Strauss BJ (1996) Body composition differences between Polynesians and Caucasians assessed by bioelectrical impedance. Int J Obes Relat Metab Disord 20(10):889–894PubMed
11.
go back to reference Stevens J, Juhaeri, Cai J, Jones DW (2002) The effect of decision rules on the choice of a body mass index cutoff for obesity: examples from African American and white women. Am J Clin Nutr 75(6):986–992 Stevens J, Juhaeri, Cai J, Jones DW (2002) The effect of decision rules on the choice of a body mass index cutoff for obesity: examples from African American and white women. Am J Clin Nutr 75(6):986–992
12.
go back to reference Boyd NF, Campbell JE, Germanson T, Thomson DB, Sutherland DJ, Meakin JW (1981) Body weight and prognosis in breast cancer. J Natl Cancer Inst 67(4):785–789PubMed Boyd NF, Campbell JE, Germanson T, Thomson DB, Sutherland DJ, Meakin JW (1981) Body weight and prognosis in breast cancer. J Natl Cancer Inst 67(4):785–789PubMed
14.
go back to reference Donegan WL, Hartz AJ, Rimm AA (1978) The association of body weight with recurrent cancer of the breast. Cancer 41(4):1590–1594. doi:10.1002/1097-0142(197804)41:4≤1590::AID-CNCR2820410449≥3.0.CO;2-N --> Donegan WL, Hartz AJ, Rimm AA (1978) The association of body weight with recurrent cancer of the breast. Cancer 41(4):1590–1594. doi:10.1002/1097-0142(197804)41:4≤1590::AID-CNCR2820410449≥3.0.CO;2-N -->
16.
go back to reference Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y et al (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20(1):42–51. doi:10.1200/JCO.20.1.42 PubMedCrossRef Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y et al (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20(1):42–51. doi:10.​1200/​JCO.​20.​1.​42 PubMedCrossRef
17.
go back to reference Hebert JR, Augustine A, Barone J, Kabat GC, Kinne DW, Wynder EL (1988) Weight, height and body mass index in the prognosis of breast cancer: early results of a prospective study. Int J Cancer 42(3):315–318. doi:10.1002/ijc.2910420302 PubMedCrossRef Hebert JR, Augustine A, Barone J, Kabat GC, Kinne DW, Wynder EL (1988) Weight, height and body mass index in the prognosis of breast cancer: early results of a prospective study. Int J Cancer 42(3):315–318. doi:10.​1002/​ijc.​2910420302 PubMedCrossRef
20.
go back to reference Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU (1994) Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 120(1):18–25PubMed Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU (1994) Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 120(1):18–25PubMed
21.
go back to reference Senie RT, Rosen PP, Rhodes P, Lesser ML, Kinne DW (1992) Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. Ann Intern Med 116(1):26–32PubMed Senie RT, Rosen PP, Rhodes P, Lesser ML, Kinne DW (1992) Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. Ann Intern Med 116(1):26–32PubMed
22.
go back to reference Suissa S, Pollak M, Spitzer WO, Margolese R (1989) Body size and breast cancer prognosis: a statistical explanation of the discrepancies. Cancer Res 49(11):3113–3116PubMed Suissa S, Pollak M, Spitzer WO, Margolese R (1989) Body size and breast cancer prognosis: a statistical explanation of the discrepancies. Cancer Res 49(11):3113–3116PubMed
23.
go back to reference Himes JH, Bouchard C, Pheley AM (1991) Lack of correspondence among measures identifying the obese. Am J Prev Med 7(2):107–111PubMed Himes JH, Bouchard C, Pheley AM (1991) Lack of correspondence among measures identifying the obese. Am J Prev Med 7(2):107–111PubMed
25.
go back to reference Gehan EA, George SL (1970) Estimation of human body surface area from height and weight. Cancer Chemother Rep 54(4):225–235PubMed Gehan EA, George SL (1970) Estimation of human body surface area from height and weight. Cancer Chemother Rep 54(4):225–235PubMed
26.
go back to reference Therneau TM, Grambsch PM (2000) Modeling Survival Data: Extending the Cox Model, 1st edn. Springer-Verlag Therneau TM, Grambsch PM (2000) Modeling Survival Data: Extending the Cox Model, 1st edn. Springer-Verlag
27.
go back to reference Collett D (2003) Modelling survival data in medical research, 2nd edn. Chapman & Hall/CRC, Boca Raton, Fla Collett D (2003) Modelling survival data in medical research, 2nd edn. Chapman & Hall/CRC, Boca Raton, Fla
28.
go back to reference Harrell FE (2001) Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. Springer, New York Harrell FE (2001) Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. Springer, New York
29.
go back to reference Vittinghoff E (2005) Regression methods in biostatistics: linear, logistic, survival, and repeated measures models. Springer, New York Vittinghoff E (2005) Regression methods in biostatistics: linear, logistic, survival, and repeated measures models. Springer, New York
31.
go back to reference Pencina MJ, D’Agostino RB (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23(13):2109–2123. doi:10.1002/sim.1802 PubMedCrossRef Pencina MJ, D’Agostino RB (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23(13):2109–2123. doi:10.​1002/​sim.​1802 PubMedCrossRef
32.
go back to reference Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37(5):360–363PubMed Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37(5):360–363PubMed
33.
go back to reference Rosner B (2000) Fundamentals of biostatistics, 5th edn. Duxbury, Pacific Grove, CA Rosner B (2000) Fundamentals of biostatistics, 5th edn. Duxbury, Pacific Grove, CA
34.
go back to reference Faraggi D, Simon R (1996) A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. Stat Med 15(20):2203–2213. doi:10.1002/(SICI)1097-0258(19961030)15:20≤2203::AID-SIM357≥3.0.CO;2-G Faraggi D, Simon R (1996) A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. Stat Med 15(20):2203–2213. doi:10.1002/(SICI)1097-0258(19961030)15:20≤2203::AID-SIM357≥3.0.CO;2-G
37.
go back to reference Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95(19):1467–1476PubMed Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95(19):1467–1476PubMed
40.
41.
go back to reference Hollander N, Sauerbrei W, Schumacher M (2004) Confidence intervals for the effect of a prognostic factor after selection of an ‘optimal’ cutpoint. Stat Med 23(11):1701–1713. doi:10.1002/sim.1611 PubMedCrossRef Hollander N, Sauerbrei W, Schumacher M (2004) Confidence intervals for the effect of a prognostic factor after selection of an ‘optimal’ cutpoint. Stat Med 23(11):1701–1713. doi:10.​1002/​sim.​1611 PubMedCrossRef
42.
Metadata
Title
Overweight, obesity and breast cancer prognosis: optimal body size indicator cut-points
Authors
Bilal Majed
Thierry Moreau
Bernard Asselain
Curie Institute Breast Cancer Group
Publication date
01-05-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0065-7

Other articles of this Issue 1/2009

Breast Cancer Research and Treatment 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine